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Abstract: Pharmacological treatment is not very effective for neuropathic pain (NP). A progressive
decrease in the estimated effect of NP drugs has been reported, giving rise to an increase in the use
of the multimodal analgesic approach. We performed a new independent review to assess whether
more and better-quality evidence has become available since the last systematic review. We evaluated
the efficacy, tolerability, and safety of double-blinded randomized controlled trials involving only
adult participants and comparing combination therapy (CT: ≥2 drugs) with a placebo and/or at least
one other comparator with an NP indication. The primary outcome assessed was the proportion of
participants reporting ≥50% pain reductions from baseline. The secondary outcome assessed was
the proportion of drop-outs due to treatment-emergent adverse events. After removing duplicates,
2323 citations were screened, with 164 articles assessed for eligibility, from which 16 were included
for qualitative analysis. From the latter, only five lasted for at least 12 weeks and only six complied
with the required data for complete analysis. CT has been adopted for years without robust evidence.
Efforts have been made to achieve better-quality evidence, but the quality has not improved over the
years. In this regard, guidelines for NP should attempt to make recommendations about CT research,
prioritizing which combinations to analyze.
Keywords: neuropathic pain; combination therapy; pharmacotherapy; randomized control trial
1. Introduction
Neuropathic pain (NP) occurs as a direct consequence of an injury or disease that
affects the somatosensory system [1]. The prevalence of NP in the population varies from
6.9% to 10%, depending on the tool used for its diagnosis [2], and it negatively affects
quality of life, impacting daily activities, such as sleeping and walking, and family and
social interactions. [3]. Patients with uncontrolled pain continuously suffer heavy individ-
ual and societal burdens, which could make them believe that chronic pain is inevitable
and untreatable, especially for those who are not responding to standard measures. A
considerable number of patients do not achieve a satisfactory pain relief or improvements
in their quality of life with currently available drugs [4]. Pharmacological therapy remains
an important component of NP management [5,6]. However, more than a decade has
passed since the market release of the last drug suggested for NP treatment, according to
international guidelines. Clinical guidelines recommend starting treatment with monother-
apy and placing combination treatment (CT) in a second tier for patients who do not
respond to monotherapy or switching [7,8].
The treatment of NP is effective in less than 50% of patients and is also associated
with significant adverse drug effects [9]. In addition, decreases in drug effect have been
reported across all drug classes, with a progressive increase in the number needed to
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treat (NNT) in randomized control trials (RCTs) [10]. The reason for this increase in NNT
numbers is not well known. This is probably due to a combination of different causes:
more complex trial designs required by regulatory agencies, such as the US Food and Drug
Administration (FDA) or the European Medicines Agency (EMA), with larger sample sizes,
longer study periods, better randomization and blinding reports, and intention-to-treat
(ITT) analysis [11–13]; more elaborated efficacy reports with an increased goal (i.e., the use
of 30% to 50% pain reduction as outcome measures) [10,14]; and the contribution of other
factors for higher levels of placebo response in NP RCTs [15].
Therefore, CT is becoming more and more popular among clinicians [16–19], and its
rationale lies on two theories: (1) a phenotypic profile-guided treatment improves symp-
tomatic control (i.e., different clinical signs and symptoms are suggested to reflect different
underlying mechanisms) and offers the possibility of an individualized mechanism-based
treatment approach for different somatosensory patterns [20–22]; (2) targeting more than
one NP mechanism simultaneously with CT could be a better approach than targeting a
single mechanism with a single drug [23,24] since it may allow lower doses of individual
drugs (due to a synergistic effect) and improve their safety/tolerability profile.
However, doubts continue to arise regarding which drug combination is effective or
which drugs to combine. For instance, some guidelines recommend adding an agent from
another class if pain control is inadequate [25]. Others state that the insufficient data do not
allow them to make any CT recommendations [17,26] or that the evidence for combinations
is inconclusive [8], with some recent recommendations for certain combinations having
weak evidence [8,16]. The last Cochrane review carried out in 2012 already indicated that,
somewhat surprisingly, they were able to identify only 107 relevant citations, from which
only 21 could be considered high-quality evidence on the matter [27].
Considering the decreasing estimates in drug effect in NP RCTs [10], the 9-year gap
since the last published Cochrane review (the previous one was published 7 years earlier,
in 2005, by Gilron et al. [28]), and the absence of a consensus among clinicians regarding
when to start CT and which drugs to combine, we thought it was appropriate to perform a
new and independent systematic review.
Hence, we performed a new independent review, searching medical databases from
2012 onwards (due to the aforementioned increases in NNT values and changes in trials’
designs). We aimed to assess the availability and quality of evidence regarding CT for NP.
Here, we make recommendations regarding CT options and propose a treatment algorithm
to guide future therapeutic decisions.
2. Materials and Methods
Even though this is a new independent review, we followed the previous systematic
review methods as closely as possible [27]. We evaluated the efficacy, tolerability, and safety
of various drug combinations for the treatment of NP. For that purpose, we identified
only RCTs of various drug combinations for NP from different databases. We also hand
searched for citations within other reviews and trial registries. The most recent search was
performed on 30 April 2021.
2.1. Criteria for Study Selection
We applied the following criteria when selecting studies for the qualitative analysis.
2.2. Types of Studies
We sought out only double-blind RCTs for the treatment of NP that compared com-
binations of two or more drugs with a placebo and/or at least one other comparator
with NP indication.
2.3. Participants
We only included studies involving adult participants 18 years and older with a
diagnosis of NP.
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2.4. Interventions
We included interventions involving a combination of two or more different drugs. We
did not include any studies performed with non-pharmacological treatments (even if they
were interventional), such as diets (including vitamin supplements) or physical measures.
2.5. Outcomes
2.5.1. Primary Outcomes
The primary outcome we assessed was the proportion of participants reporting
≥50% pain reduction from baseline. When 50% pain reduction was not reported, we
looked for a decrease in pain by ≥30% from the baseline.
2.5.2. Secondary Outcomes
We looked for (i) the proportion of drop-outs due to treatment-emergent adverse ef-
fects and (ii) the proportion of participants reporting each specific adverse effect (i.e., sedation
and dizziness) with moderate or greater severity.
2.6. Search Methods
We searched the following databases, timelines, and restrictions:
• PubMed®. Search keywords: (“neuropathic pain” AND “combination”). The timeline
was limited to articles published from 1 January 2012 to 3 March 2021. Language filter:
English. The last search was performed on 3 March 2021.
• Google Scholar. Search keywords: (“neuropathic pain” AND “combination therapy”).
The timeline was limited to articles published from 2012 to 2021. Language filter:
English. The last search was performed on 15 March 2021.
• Web of Science. Search keywords: (“neuropathic pain” AND “combination therapy”).
The search was performed on all databases except for the zoological one. The timeline
was limited to articles published from 2012 to 2021. Filters were applied to exclude
review articles, case reports, editorial material, books, meetings, and letters and
corrections. Language filter: English. The last search was performed on 30 April 2021.
• SCOPUS. Search keywords: (“neuropathic pain” AND combination) in the title, ab-
stract, or keywords. The timeline was limited to publication years after 2011. Filters:
document type “articles” and only English language. The last search was performed
on 30 April 2021.
• We further searched ClinicalTrials.gov. Keywords: (“neuropathic pain” AND “combi-
nation therapy”). No filters were used. The last search was performed on 3 March 2021.
• We searched within the reference lists of all the included studies.
• Finally, we also checked for relevant citations within other reviews and meta-analyses
published between 2012 and 2021.
2.7. Data Collection and Analysis
All citations were screened by title and, when not directly excluded, by abstract to
be assessed for eligibility by the corresponding author (A.S.A.). From those assessed for
eligibility, A.S.A. and S.V. performed a second thorough selection for qualitative analysis.
All selected studies were checked independently by the three authors for criteria fulfillment
for qualitative analysis, and a triple cross-check was performed afterwards. Data extraction
from selected studies was performed by S.V. and T.C. and, again, cross-checked afterwards.
2.7.1. Data Extraction
From each selected study, using the aforementioned criteria, we extracted the following data:
• The proportion of participants with 50% pain relief (primary outcome);
• The proportion of participants with 30% pain relief (whenever 50% was not reported
and even if 50% was reported);
• The proportion of drop-outs due to treatment-emergent adverse events (secondary outcome);
• The proportion of dropouts for any other reason (secondary outcome);
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• The proportion of participants reporting each specific adverse effect (i.e., sedation and
dizziness) with moderate or greater severity; and
• The study drugs, including the names, doses, routes of administration, and
treatment durations.
2.7.2. Risk of Bias
We searched for the following types of bias in all of the studies included for qualitative
analysis: random sequence generation and allocation concealment (selection bias), blinding,
incomplete outcome data, selective reporting, and other potential sources of bias. We
graded all selected studies for quality per the Cochrane Risk of Bias tool [29].
2.7.3. Measures of Effect
We sought for comparative effects between CT study drugs and their comparators,
which could be either a placebo or the individual drugs that comprise the CT.
2.7.4. Unit of Analysis
For those studies with more than one active treatment group, we divided the control
group among the active treatment arms to allow comparison between them.
2.7.5. Missing Data
We analyzed the data based on ITT. We considered all randomized patients in the ITT
population who received assigned treatments that provided at least 50% of the required
outcome data.
2.7.6. Heterogeneity
To avoid heterogeneity, we did not assess any study that did not have similar condi-
tions for analysis.
2.7.7. Groups and Subgroups
We looked for any subgroup that could produce a different combination of study
results (i.e., phenotyping). Finally, for the discussion, even if grouping was not possible, we
categorized studies according to the drug classes used for CT (i.e., opioids, antidepressants,
anticonvulsants, etc.).
3. Results
3.1. Description of Studies
The steps taken during this research are summarized in Figure 1 . We identified a
total of 3808 citations, including records from databases and additional records from other
sources, ending the search on 30 April 2021. After removing duplicate citations, we ended
up with 2323 individual citations to screen. After thorough screening, we assessed a total
of 164 articles for eligibility, out of which 16 were included for qualitative analysis. Only six
of them complied with the requirements of data (primary outcome) for complete analysis.
No data could be added up or combined for quantitative analysis. Hence, no meta-analysis
could be conducted.
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Figure 1. PRISMA flow diagram.
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3.1.1. Study Selection
We identified 16 studies that fulfilled the inclusion criteria for this review: RCTs,
double-blinded, and a comparison of combinations of two or more drugs with a placebo
and/or at least one other comparator for the treatment of NP [30–45]. Among them,
only six provided data on the primary outcome (proportion of participants reporting
≥50% or ≥30% pain reductions from baseline), either by direct reporting or by deduc-
tion through study figures or graphs (data from such studies can be seen in Table 1).
In total, 1243 participants were included in the study drugs groups vs. 928 were in-
cluded in the control groups: one RCT evaluated the combination of cannabinoids delta-
9-tetrahydrocannabinol (THC)/cannabidiol (CBD) oromucosal spray and the existing
treatment regimen for central neuropathic pain (CNP) in patients with multiple sclero-
sis [43]; a different drug combination (opioid plus pregabalin (PGB) plus duloxetine (DXT)
was tested in one RCT in NP in cancer patients [32,40]; one tested a combination of DXT
and PGB against both of them on monotherapy in painful diabetic neuropathy (PDN) [42];
another compared a drug combination of dextromethorphan and quinidine against a
placebo, again in PDN [45]; and capsaicin 8% dermal patch (CP8) in combination with sys-
temic NP medications was evaluated in another RCT in postherpetic neuralgia (PHN) [44].
Likewise, these studies also provided data on the secondary outcomes: (i) the proportion
of participants dropping out of the study due to treatment-emergent adverse effects and
(ii) the proportion of participants reporting each specific adverse effect (i.e., sedation and
dizziness) with moderate or greater severity.
3.1.2. Study Design
Among the selected RCTs, twelve studies [30,32–36,39,40,42–45] used a parallel design
and four [31,37,38,41] used a crossover design. None of the crossover trials conducted
analyses involving only first period data, likely due to inadequate statistical power.
Among the six RCTs that provided data on the primary outcome, three compared the
combination of interest with the placebo alone [43–45]; one compared a combination of
two drugs against monotherapy of each drug and the placebo [38]; another one compared
CT only against high-dose monotherapy of each, with no placebo control [42]; and the last
one compared the combination of three painkiller drugs with the combination of only two
of these painkiller drugs in cancer patients with NP [32]. It is noteworthy that only three of
them had a treatment period of at least 12 weeks, excluding the titration period [43–45].
3.1.3. Outcomes
Five studies reported the number of patients with a ≥50% pain reduction [38,42–45],
and in other studies, this number was deduced from the figures [32]. Most of these studies
also reported the number of patients with ≥30% pain reduction, except for two stud-
ies [38,43]. One study described the proportion of patients reporting ≥50% pain reductions
and ≥30% pain reductions, but these proportions were assessed using a secondary analysis
producing the overall percentage from all treatment groups on a three-branch crossover
study. The number of participants could not be calculated from this percentage or from
the diagram of participants included and withdrawn from the study [37]. Other outcomes
such as adverse effects and the patient’s overall impression of the change in pain relief are
shown in a table in the Supplementary Materials (Table S1).
According to the guideline on the clinical development of medicinal products intended
for the treatment of pain [46], a sustained therapeutic effect in chronic pain should, in
general, be demonstrated in pivotal efficacy trials with a treatment period of at least
12 weeks [47]. Five out of sixteen selected RCTs provided data on a period of at least
12 weeks [30,34,43–45], all with a parallel design.
3.1.4. Pain Conditions
PDN was explored in three studies [30,42,45], PHN was explored in one study [44],
neuropathic cancer pain (N-CP) was explored in three studies [32,33,40], lumbar spinal
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stenosis (spinal cord injury (SCI) pain) or low back pain were explored in two studies [35,36],
CNP was explored in two studies [39,43], other different neuropathic conditions were
evaluated in four RCTs [34,37,38,41], and one condition was evaluated in long-standing
NP [31].
3.1.5. Excluded Studies
For the purpose of this review, we did not include any other intervention that was not
about drug CT for NP. Thus, independent of whether they were RCTs or not, all studies
that used other comparators such as diet, vitamins, non-medical therapy (i.e., physical
therapy), and any kind of interventional therapy (i.e., neuraxial, nerve blocks, etc.) were
not included for analysis. We also excluded studies that compared CT for NP but were not
RCTs (i.e., observational analysis, cohort studies, retrospective analysis, open label, etc.).
Post hoc analyses of other RCTs were excluded too.
Of the 16 selected RCTs that fulfilled the inclusion criteria of this review, 10 were
excluded because they did not provide data on the primary outcome [30,31,33–37,39,41,45].
Even if an RCT reported other pain assessments (such as Patient Global Impression of
Change (PGIC), Brief Pain Inventory (BPI), or both) but not the primary endpoint (≥50%
reductions in pain from baseline), when it was not reported, then that RCT did not meet
the criteria to be included in the full analysis. The data on these non-selected studies are
shown in Table 2. Therefore, this review focused only on six studies [32,40,42–45], from
which only three RCTs provided data from a period of at least 12 weeks [43–45].
3.2. Risk of Bias
The risk of bias is shown in Table 3. Judgements about each item in the assessment
of risk of bias presented as percentages across studies can be found in the Supplementary
Materials (Figures S1 and S2).
3.2.1. Random Sequence Generation and Allocation Concealment (Selection Bias)
Four of the six studies reported the method used to generate the random sequence
and to keep the allocation concealed [32,38,42,44]. The other two appropriately reported
only one or the other [43,45].
3.2.2. Blinding
Only one study [40] was not blinded. Among the other studies, although all of them
claimed to be blinded, 5 out of 15 studies [30,35,36,41,45] did not describe the blinding
procedure.
3.2.3. Incomplete Outcome Data
We qualified attrition bias as “low risk” for studies where the dropout rate was below
20%. We qualified studies with higher dropout rates but included ITT analyses as “unclear”
or “high risk of bias”. All six studies provided information about trial dropouts.
3.2.4. Selective Reporting
Although four out of the six selected studies [32,38,42,43] indicated pre-trial registra-
tion on a clinical trial registry, all six of them reported on at least one of the outcomes that
was considered to be clinically relevant.
3.2.5. Other Potential Sources of Bias
We assessed the issue of other bias as being high risk in studies where the follow-up
was shorter than twelve weeks [32,38,42] and/or where the study had fewer than 50 partic-
ipants per arm or period of treatment in parallel or crossover studies, respectively [32,38].
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Table 3. Risk of bias.
Study Bias Arising from theRandomization Process
Bias Due to Deviations
from Intended
Interventions









Langford 2013 [43] + + + + ? ?
Irving 2012 [44] + + + ? ? ?
Shaibani 2012 [45] + + + + + +
Tesfaye 2013 [42] + + + + ? -
Holbech 2015 [38] + + + + ? -
Matsuoka 2019 [32] + + + + ? -
Singh 2021 [30] ? - - + ? -
Rigo 2017 [34] + + + + ? .
Kim 2016 [35] + + + + ? -
Baron 2014 [36] ? + + + ? -
Gilron 2015 [37] + + + + ? -
Pickering 2020 [31] + + + + ? -
Turcotte 2015 [39] + - + + + -
Harrison 2013 [41] + - + + ? -
Dou 2017 [33] + + + + ? -
Garassino 2013 [40] ? - + ? ? -
This table reproduces our judgements about each risk of bias item for each study. + with a green background stands for a low risk of bias. ? with a yellow background stands for unclear risk of bias. - with a red
background stands for a high risk of bias.
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3.3. Effect of Interventions
When combining THC/CBD oromucosal spray as an add-on with a pre-existing
regimen for central neuropathic pain, the number of responders (≥50% pain reduction
from baseline) at week 10 totaled 30% in the THC/CBD spray group compared with 28%
in the placebo group (p-value: 0.714). Therefore, there was no difference between treatment
groups, mostly due to a similar (high) number of placebo responders [43].
For a 12-week period, in patients who used systemic pain medication, CP8 as an
add-on therapy reduced NP in PHN. The number of responders (≥50% pain reduction
from baseline) was 29% in the CP8 group and 17% in the placebo group (p-value: 0.048).
Likewise, CP8 reduced NP in PHN in patients who did not use systemic medication (36%
for CP8 group, 25% for placebo group, p-value: 0.004) [44]. We could not differentiate
between concomitant medications. No data in this regard were given.
A combination of dextromethorphan and quinidine was effective, with an acceptable
safety profile, for the treatment of PDN pain. The proportion of patients who achieved a
50% rating scale score reduction was 66% (DMQ 45/30 mg twice a day) and 54% (DMQ
30/30 mg twice a day), compared with the placebo group (p-value: 0.001 and 0.006,
respectively) [45].
A combination of PGB+DXT showed no significant differences in pain reduction
in patients with PDN when compared with either PGB or DXT at high-dose monother-
apy. The number of responders (≥50% pain reduction from baseline) was 52% in the
“60 mg DLX + 300 mg PGB” group, 51% in the “300 mg PGB + 60 mg DLX” group, 29% in
the “60 mg DLX + 60 mg DLX” group, and 47% in the “300 mg PGB + 300 mg PGB” group
(p-value: 0.068) [42].
A combination of moderate doses of the tricyclic antidepressant (ATC) imipramine
and PGB could be considered an alternative to high-dosage monotherapy for painful
polyneuropathy. The percentage of patients who had at least 50% relief with respect to
baseline was placebo 6%, PGB 12%, imipramine 20%, and CT 28% [38].
Adding DXT to opioid–PGB therapy might have clinical benefits in alleviating refrac-
tory N-CP. The proportion of patients who achieved 30% or more pain reduction was 37.5%
in patients eventually receiving PGB and DXT, 60% in those receiving DXT only, 23.1%
in those receiving PGB only, and 0.00% (90% CI 0.00–40,96) in those receiving placebo
only [32]. However, this effect was assessed only for 10-day therapy. No information was
presented for a longer period of treatment.
4. Discussion
In this review we tried to identify new RCTs that could bring new evidence on
CT for NP published after the last Cochrane’s systematic review in 2012 [27]. After a
thorough data search from various databases, we could only find 16 RCTs, of which
only 5 directly reported the primary outcome and, in 1 RCT, the primary outcome had
to be deduced from the figures. In addition, out of the 16, only 5 RCTs reported pain
outcomes after 12 weeks [30,34,43–45], as required by the standards. We were not able to
perform a quantitative analysis (meta-analysis). The main reasons were the small number
of trials included and the heterogeneity among them, not only on the drug types and
combinations used, but also on type of pain and type of study, which made accomplishing
a meta-analysis impossible.
4.1. Main Results
We can assume that adding THC/CBD to a pre-existing treatment for NP has no effect
and that no difference between a PGB–DXT combination exists against either drug on
high-dose monotherapy. However, a combination of an ATC such as imipramine and PGB
may be an alternative to high-dose monotherapy. Likewise, adding DXT to a previous
opioid–PGB therapy may be beneficial too, and topical CP8 for peripheral NP is effective in
reducing NP regardless of the concomitant therapy. Different unusual combinations such
as dextromethorphan and quinidine may be another useful treatment option.
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For the secondary outcomes, all the selected studies had safety reports, where they
differentiated adverse effects and drop-outs due to treatment-emergent adverse effects
(only one for the latter) [32]. However, the data on prescribed rescue medication were
either not available [42] or not analyzed [42–44]. Other pain ratings or sleep interferences
were evaluated in some studies. A PGIC was evaluated in three studies [42–44], and the
BPI was evaluated also in three studies [32,42,43]. Sleep interference was evaluated in four
studies [32,42,43,45]. On the other hand, NP symptoms or sensory testing was reported
only in one study [38], whereas the data were unclear in another two studies [42,43].
4.2. Quality of Evidence
In this review, before obtaining any results, we initially intended to perform a system-
atic review and meta-analysis. At first, we doubted if we should include in our quantitative
analysis the studies already previously reviewed. As the NNT has changed, stabilizing
after 2010 [10], we thought that a new separate independent and analytical review would
be wiser. However, after the screening and selection, we found that a meta-analysis would
not be possible. Thus, the quality of evidence has not increased after all these years. Never-
theless, some good-quality studies have demonstrated the superior efficacy of two-drug
combinations against a placebo and against monotherapy.
Ten studies had very small treatment groups [31–35,37–41]. The impact of small
numbers on the effect cannot really be calculated, and it can overestimate treatment
effects [48]. Half of the studies did not report the primary outcome (i.e., ≥50% or ≥30% pain
reductions from baseline), more than half did not report a comparison with a period of
experimental treatment versus the comparator for 12 weeks or longer, and the one study [45]
with a comparison period of 12 weeks or longer did not report the primary outcome. It
is noteworthy that a recommendation was already made in 2012: a sustained therapeutic
effect in chronic pain should be demonstrated in pivotal efficacy trials with a treatment
period of at least 12 weeks [47].
As we did not find several available studies with good-quality evidence for any one
specific combination, we could not conduct any quantitative analyses even if we added the
previous systematic review [27]. Therefore, we cannot make any recommendations on any
specific drug combination for neuropathic pain over another.
4.3. Data from the Other Unselected Studies and Articles Assessed for Eligibility
As it was not possible to perform a systematic review and quantitative analysis from
the selected studies, we took one step back and looked at evidence in the other 12 studies
and other relevant open-label or observational studies published within this period, which
were assessed for eligibility but not included for the qualitative synthesis. Even though the
conclusions from those studies are not enough to make strong recommendations, they may
be useful in guiding further studies.
4.3.1. Cannabinoids in Combination
One of the results of this review is that adding THC/CBD to a pre-existing treatment
for NP did not show any benefits for these patients [43]. On the other hand, a recent
review on only nabiximol (THC/CBD) for NP found that it was superior to the placebo
but with a small effect size [49]. This small effect size alone may be the reason why it is
not useful in combination. Moreover, there may be a difference between whether the CT is
used with THC alone. Nabilone, a synthetic THC analogue, added to gabapentin (GBP)
could be beneficial [39], but again, the results were produced from a very small number
of participants, and the study was performed only for nine weeks. Findings indicating
that GBP synergistically enhances THC have also been reported [50]. Thus, THC, but not a
combination of THC/CBD, may represent a potential adjuvant for NP medications.
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4.3.2. Topical Treatments in Combination
Evidence for other topical treatments in CT is also controversial. Apart from the RCTs
selected in this review, where CP8 was demonstrated to reduce NP as an add-on ther-
apy [44], we also found three other non-selected studies on a lidocaine 5% plaster [51–53],
one retrospective analysis on transdermal buprenorphine [54], and a very recent study
protocol of a study combining clonidine and pentoxifylline [55]. One of the lidocaine
5% plaster studies [51] and the transdermal buprenorphine study not only were retro-
spective but also had a low number of participants, with different pain conditions and
several concomitant therapies. Therefore, they were not suited for drawing any conclusions.
Another retrospective study using a lidocaine 5% plaster as an off-label add-on therapy
for different localized NP syndromes and conducted with 130 patients found that only 79
were still on the plaster after 3 months (44 after a year) [52]. Nevertheless, out of the 130, 66
reported >30% pain relief, from which 39 reported >50%. Despite being retrospective, this
study suggests that lidocaine 5% plaster as an add-on therapy could have the same effect
as CP8. Furthermore, an RCT for lidocaine 5% plaster against the placebo did pinpoint
some findings about its use [53]. Randomization was stratified by concomitant treatment
status, and no significant differences were found among the study groups, even though the
treatment arm experienced better pain relief. A subgroup analysis showed that the add-on
therapy group behaved almost the same as the placebo group. Hence, the results from the
available literature on lidocaine 5% plaster are heterogeneous and inconsistent and should
be clarified in a proper RCT for CT.
4.3.3. Gabapentinoid and Opioid Combinations
The findings on the association of gabapentinoids with opioids are inconclusive. One
RCT with a small number of participants and carried out for only 14 days showed that
adding PGB to morphine in an N-CP was useful in reducing morphine dosage [33]. This
morphine dose reduction was also suggested in a retrospective analysis [56]. However, the
efficacy was the same between the CT and using morphine alone. An open-label study
with morphine and PGB against both drugs in monotherapy under different NP conditions
showed that CT was similar to morphine and superior to PGB in monotherapy [57],
although this study, in addition to being open-labeled, had a very high drop-out rate in
both monotherapy arms. A similar finding was reported for an eight-week non-inferiority
RCT where tapentadol alone showed no difference when compared with a combination
of tapentadol plus PGB [36]. No comparisons were made for the PGB alone or with the
placebo. Unfortunately, even though this RCT showed a decrease in mean changes in pain
intensity in both arms, the primary outcome for selection in this review was not shown,
and we could not deduce it from the figures or tables. On the contrary, two open-label
observational studies that added PGB to the pre-existing treatment [58,59] and another
that added oxycodone/naloxone to patients already taking gabapentinoids [60] reported
a decrease in pain. However, neither of them were actual RCTs (i.e., no placebo and no
randomization). As a result, we can say that little to no difference is found in efficacy when
combining gabapentinoids with opioids, whereas it may be a useful leverage for opioid
dose reduction.
4.3.4. Antidepressant and Opioid Combinations
The literature on antidepressants and opioids is limited too, but the results are more
consistent towards a benefit for CT. In fact, combining antidepressants, be they tricyclic
or otherwise, with opioids is a more frequent combination than combining antiepileptics
with opioids [61]. Whilst DXT and methadone reduce cancer-related pain when compared
with each drug alone (monotherapy) [62], adding DXT to an opioid–PGB therapy might
have clinical benefits in alleviating refractory N-CP [32], and a superior efficacy of a
nortriptyline–morphine combination has also been reported over each of these drugs
in monotherapy [37]. Another RCT with a DXT–methadone combination could not be
completed due to recruitment and retention issues [41]. Even though little evidence exists,
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the quality seems better for CT with antidepressants plus opioids than for gabapentinoids
plus opioids.
4.3.5. Gabapentinoids and Antidepressants in Combination
Another very frequently found combination is the one between gabapentinoids and
antidepressants [61,63]. In fact, combinations of PGB/GBP and DXT/TCAs have been
previously recommended for consideration as an alternative to increasing dosages in
monotherapy for patients unresponsive to monotherapy with moderate dosages [8]. The
American Academy of Neurology (AAN) guidelines have recommended adding venlafax-
ine to GBP in patients with inadequate pain relief on GBP monotherapy [64]. Recent
evidence is contradictory, and recommendations may need to be reconsidered. An RCT
selected in this review demonstrated the superiority for CT with PGB and imipramine. [38].
This RCT, though, had a low number of patients per arm, and the test lasted only for
5 weeks. The period was too short to show a persistence of the effect. Even so, PGB and
imipramine in moderate doses was significantly superior to either drug in moderate-dose
monotherapy. In another cohort study, PGB superadded to a pre-existing amitriptyline
regimen helped to reduce pain [65]. However, though the authors claimed that the study
was a randomized placebo-controlled study, the blinding and randomization procedures
were not described properly. In addition, other recent contradictory results have been pre-
sented. In a post hoc analysis of another previous non-inferiority trial for DXT against PGB,
patients treated with DXT plus GBP showed greater pain reduction than PGB monotherapy
but not to DXT monotherapy, which was even more effective in patients who previously
did not take any type of antidepressant [66]. Additionally, one of the other selected RCTs,
the COMBO-DN study, did not find any statistically significant difference between the
combination of DXT with PGB and high-dose monotherapy of either of them [42]. This RCT
had some biases that made the results difficult to interpret. The result only lasted 8 weeks
within the comparison period, no comparison for CT against low doses monotherapy
was made, and the drop-out rate was high for several reasons: 109 out of 804 (13.5%) of
the initial participants were drop-outs due to adverse effects, 10 dropped out due to a
lack of efficacy, 42 dropped out due to patient decision, 64 dropped out for other reasons
(noteworthily, 12 of them were withdrawn despite presenting a “satisfactory response”
just before completion of the trial, and this issue, far from being odd, also appears in
another selected study [44]), whereas only 290 completed the study out of 804 initially
randomized. Additionally, in another cohort study, a combination of anticonvulsants and
antidepressants was not associated with improved pain control at 6 months compared with
individual therapy [67]. After considering these heterogeneous results, we are not sure re-
cent evidence is strong enough to support recommendations on combining antidepressants
with gabapentinoids. If a need for such combinations exists, the evidence shows it may be
better to combine gabapentinoids with tricyclics.
Nevertheless, whether PGB should be added to the treatment of refractory uncon-
trolled pain, with an already broad treatment profile, remains to be answered. This was
reported, with a relevant improvement in pain and treatment satisfaction, in two large
observational studies [58,68], and neither TCAs nor opioids were found to be predictive
factors for adverse events associated with PGB [69]. However, a re-analysis with pooled
data from several RCTs showed that the therapeutic response to PGB was unaffected by
concurrent NP medications and that the appearance of adverse events was unaffected
too [70].
4.3.6. Other Combinations
Finally, some interesting studies on other CTs have been performed, such as the combi-
nation of limaprost (prostaglandin E1 analog) with PGB, which did not provide additional
relief in symptoms when compared with monotherapy with each of these drugs [35]. A
combination of methadone and the N-methyl-D-aspartate (NMDA) antagonist ketamine
was not better compared with methadone or ketamine alone [34], although the number of
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participants was low (14 on each arm). Either way, in a recent RCT, both ketamine alone and
in combination with magnesium were found to not provide pain relief [31] despite a short
5-week study period. DXT and PGB, again in monotherapy, were compared, also recently,
against a combination of either one with epalrestat (an aldose reductase inhibitor approved
in some countries for the improvement of subjective neuropathy symptoms associated with
diabetic peripheral neuropathy) [30]. That study demonstrated that PGB and epalrestat
therapy had better effects on NP reduction than DXT and epalrestat within 3- and 6-month
periods, but we could not figure out whether a significant difference against monotherapy
was found. We also could not find information on the number of responders or drop-outs.
The other RCT included for qualitative analysis but not for complete analysis due to not
meeting the requirements compared two doses of a combination of dextromethorphan and
quinidine [45]. A comparison against the placebo but not against monotherapy was made.
Nevertheless, these drugs in combination are not among those recommended by clinical
guidelines. Therefore, recommendations in this regard must be made with caution.
4.4. Implications for Clinical Practice
The burden of NP seems to be related to the complexity of neuropathic symp-
toms, poor outcomes, and difficult treatment decisions. Importantly, quality of life is
impaired in patients with NP owing to increased drug prescriptions and visits to healthcare
providers [71]. Published guidelines up until now recommend starting treatment with
monotherapy [7,8,25,26]. If the first treatment is ineffective, the recommendation most
frequently given is to switch drugs for another first-line treatment. However, some con-
troversies exist about what to do in case of poor efficacy. After reaching the maximum
tolerated dose, in clinical practice, for the management of NP, a second or even a third drug
in combination regimens are frequently added [5,6,19].
Little evidence regarding CT exists. Despite the different treatment options available
for NP, many patients do not experience clinically significant pain relief. In addition, they
often experience adverse effects that make them unable to tolerate treatment [72]. Thus,
clinicians often resort to concurrent administration of more than one pharmacological
agent [58,73]. Combinations of analgesics used simultaneously in acute pain have been
demonstrated to provide additive pain relief [74,75], and combination analgesics are among
the most effective drugs in acute pain [76]. Given the evidence that a considerable number
of patients with NP receive two or more drugs [61,63], we were only able to identify
16 recent relevant citations for this review and only 6 high-quality NP RCTs that evaluated
the strategy of CT. Even more surprisingly, almost 10 years after the last review was
published [27], these problems have not been addressed, and clinicians still need to rely on
low-quality evidence and empirical knowledge when it comes to prescribing CT for NP.
Nevertheless, with the current evidence, we suggest a flow diagram for those in need
of starting CT. This proposal is based on the results of this review and is only intended
to serve as a guide. Our aim with this review was not to make any recommendations.
The flowchart begins with a patient who is already on antidepressants or on opioids as
concurrent medication (Figure 2). The option for those who are already on gabapentinoids
or on duloxetine is not shown. Evidence in this regard is inconclusive and controversial.
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Figure 2. A guide presented as a flowchart for a strategy for combination therapy for neuropathic pain. This flowchart is a
strategic proposal for prescribing combination therapy for neuropathic pain that begins with a patient already on opioids or
tricyclic antidepressants. The option for those who are already on gabapentinoids or on duloxetine is not shown. Evidence in
this regard is inconclusive and controversial. This flowchart is a proposal drawn from the recent evidence presented in this
review. Clinicians should consider that this guide may (and should) change as new evidence is brought to light. # = While
in this review we did not find published evidence on lidocaine patches, these should be considered where appropriate
by previously published evidence. * = Evidence on opioid combination therapy is controversial and inconclusive. From
recent evidence, these seem to be the best available options. TCAs = tricyclic antidepressants, NP = neuropathic Pain,
DLX = duloxetine.
4.5. Implications for Research
In order to properly identify specific CT that provides superior efficacy and/or safety,
we recommend that future NP studies of two-drug combinations include comparisons with
placebo and both single-agent components. When designing the study protocol, before
calculating the sample size, researchers should consider that pain RCTs have a higher
placebo response [15] and that claims about an increase in drop-out numbers have been
made [38,41,42]. Moreover, a crossover trial takes longer than a parallel one, increasing the
chance of more dropouts.
In addition, we encourage NP guidelines to include recommendations of which NP
CT to study, so that better evidence can be reached, and meta-analyses can be conducted
afterwards. Reports of widespread clinical NP CT benefits provide an impetus for ad-
ditional future investigations. Regarding this matter, a demonstration of CT benefits by
several studies in animals could also provide a rationale for studies in this and other
directions [50,77–85].
For instance, in non-clinical studies, the potentiation of morphine by GBP has been
validated in a chronic constriction injury model of NP [77,78]. Likewise, the combination
of GBP and tramadol in a partial sciatic nerve ligation model [79], peripheral neuropathy
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induced by paclitaxel [80], and diabetic neuropathy [81] has been validated. Furthermore,
no significant drug-to-drug interaction between PGB and tramadol has been studied in
healthy volunteers [86], and surprisingly, a recent proposal to make a compound tablet
with tramadol and GBP was put forward [87], even though these combinations have not
yet been validated in proper RCTs.
Similarly, other combinations have been also tested in animal models. THC (with
no CBD) and GBP reduced mechanical and cold allodynia in a chronic constriction injury
model but without diminishing the THC-related side effects [50]. Another pan-cannabinoid
receptor agonist, when administered together with morphine, reduced allodynia in a
synergistic manner but had only an additive effect on motor incoordination [82]. The same
agonist had supra-additive effects on cold allodynia in a post-operative model combined
with a selective noradrenaline reuptake inhibitor [83].
Finally, researchers could also try different combinations. CT with two or more classes
of antiepileptics is common in clinical practice for epileptic disorders. This combination
has not been fully explored in NP. Regarding this matter, some results have been found in
a nerve ligation model, where carbamazepine and PGB synergistically ameliorated NP at
higher doses [84]. In addition, NMDA receptor antagonists, together with GBP, have also
provided synergistic effects in the alleviation of NP in a SCI model, while reducing side
effects [85].
Moreover, research on phenotypes responding to treatment may provide further
suggestions about CT for NP. Even among individuals with seemingly singular neuro-
pathic conditions (e.g., PHN), substantial diversity exists with respect to various clinical
manifestations, sensory examination features, and presumably underlying pain mecha-
nisms [21,22]. For instance, recently, Benavides et al. found a functional polymorphism
that could predict pharmacologic response to a combination of nortriptyline and morphine
in NP patients [88].
4.6. Potential Biases and Limitations
We tried to scope the results of this review in the most objective way possible. How-
ever, we had some difficulties finding data. First, some trials were found after the third
or even the fourth database search. Therefore, though unlikely, the possibility of missing
RCTs still exists. As we could not afford the fee to search EMBASE, we may have missed
information. Additionally, as the search was already very large, we did not include other
websites (e.g., controlled-trials.com, and clinicalstudyresults.org). Thus, we may have
missed some RCTs. This can lead to a publication bias. However, we considered that, as the
search was conducted on four major databases with over 2000 different citations and over
1500 duplicated results, the probability of missing a trial was very low and the amount
of work and duplicates would increase even further. Another difficulty we found was
looking for proper data within the publications. Some data were very accessible, but other
data needed to be inferred via tables, figures, or even the discussion. Thus, even after a
colleague (see the Acknowledgments) reviewed our work, we may have made mistakes
with the discernment of extracted data.
Another serious limitation was complying with all items for a systematic review. We
did not register the protocol for this review in a review registry (e.g., PROSPERO). This is a
critical flaw according to AMSTAR-2 [89]. Even so, we have tried to reflect, in the material
and methods section, the entire search protocol as it was carried out. For conducting
a proper systematic review, we missed item 2 (protocol registration), whereas items 4
(literature search) and 7 (justification for excluding individual studies) were partially
fulfilled, but it only remains an issue for reviewing those studies conducted only after 2012.
We also could have performed a thorough meta-analysis including all the RCTs
published prior to 2012 [27]. By doing this, we may have achieved a systematic review and
a quantitative meta-analysis. Chaparro et al. performed one with only two RCTs. However,
given the changes in trial methodology and requirements by EMA and FDA and that
the NNT has increased (accompanied by a decrease in effect size), which stabilized after
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2010 [10] we thought that not including those studies would be wise. Even though this may
lead to a discussion about publication bias, mixing those trials could generate more bias
and confusion than benefits. Maybe we should have been more thorough and included
studies published after 2010. However, trying to conduct a complete meta-analysis based
on individual data, not by sizing up several RCTs but by shelling individual data from
every RCT and only then conducting the complete meta-analysis, would be wiser. This
work is very time-consuming simply regarding retrieving individual data from old records,
and we could not afford to do so. We recommend that other researchers follow this path
for the purpose of obtaining better evidence on CT for NP.
Finally, we decided to keep the primary outcome strictly as the proportion of partici-
pants reporting ≥50% pain reductions from baseline (or ≥30% when 50% was not reported)
and did not add other pain evaluations such as moderate or greater pain relief, or moderate
or greater overall improvement, for the purpose of obtaining stronger evidence. In fact,
the latest review used these other options as primary outcomes [27]. If we had added
these criteria in the primary outcome, we could have gathered more studies. However, we
believe that a study with measures of pain reduction as the primary outcome but not re-
porting the number of participants with that pain reduction in their results to be awkward.
Hence, not reporting these numbers would give these awkward studies the same status
as other studies that did report such an endpoint. If regulatory agencies have raised their
standards for conducting RCTs from ≥30% to ≥50% pain reductions from baseline, we
inferred that a systematic review should raise the primary endpoint too. Consequently, we
made the primary objective simple and highly selective. As said before, the risk of doing
so is leaving some good studies out. However, reporting the number of participants with a
pain reduction is an important issue in pain trials. Reporting the number of participants
with a reduction in other scores such as overall improvement or pain relief is also useful,
but reporting the most important outcome should not be compromised.
4.7. Agreements or Disagreements with Other Studies or Reviews
We completely agree with Eisenberg and Suzan’s review. Even though several new
trials have used various drug combinations for NP, the results are still inconsistent due to
methodological problems [24]. We partially agree with the review by Finnerup et al. [8].
In recent years, no trials have been conducted on GBP CT. A combination of PGB with
TCAs may be one option, whereas its combination with DXT (or other selective serotonin
noradrenaline reuptake inhibitors) has yet to be elucidated.
In a review on topical treatments for localized neuropathic pain conducted by Casale
et al., the evidence to support systematic use as treatment options was still insufficient [90].
Now, after reviewing the selected and other recent non-selected studies, we think that CP8
may be used systematically as an add-on therapy.
We do not agree completely with the conclusions of Guan et al. regarding anticonvul-
sants or antidepressants, in which they claim that CT reduces NP [91]. Even though their
systematic review and meta-analysis was conducted only for NP in cancer patients, only
three of the eight selected studies used drug combinations as experimental compounds.
We found that the evidence for this topic remains controversial.
Again, more than nine years after the last review, we continue to agree with the
conclusions of that last systematic review [27]. For this period, the total number of citations
may have increased, but the number of high-quality NP RCTs that evaluated the strategy
of CT has not. Again, in our review, only one eligible study evaluated a combination
of the two most widely used classes of neuropathic pain drugs, i.e., antidepressants and
anticonvulsants. Additionally, once again, the paucity of recent available studies for each
drug class combination studied from the last review until now precludes any well-founded
conclusions about most combinations. The search strategy for this review was not designed
to capture all studies available to date but only those published after 2012; therefore, another
review that includes all studies published to date may produce different conclusions.
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However, as mentioned before, we designed this review according to changes that may
have influenced RCTs. Combining recent and older RCTs may also generate confusion.
5. Conclusions
Neuropathic pain treatment continues to be an unmet medical need, as patients
keep reporting inadequate pain relief. Clinicians continue to have problems dealing
with how to face pharmacological strategy when first-line treatment fails. CT has been
a practice adopted for many years for which the evidence is not solid. Efforts have been
made to achieve better-quality evidence, but the quality has not improved over the years.
Guidelines for neuropathic pain should attempt to make recommendations about CT
research, prioritizing which combinations to analyze over others, so that the search for
better evidence can take steps forward.
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